Cybin secures U.S. patent for program targeting generalized Anxiety disorder and depression скачать в хорошем качестве

Cybin secures U.S. patent for program targeting generalized Anxiety disorder and depression

Cybin Inc. CEO Doug Drysdale joined Steve Daring from Proactive to announce that the United States Patent and Trademark Office has granted U.S. patent 12,318,477, bolstering the company’s intellectual property portfolio around its CYB004 program. CYB004 is a deuterated DMT compound being developed for the treatment of generalized anxiety disorder. The patent, which offers protection until 2040, includes claims covering novel formulations of DMT and deuterated isotopologues for intramuscular (IM) injection. Drysdale explained that IM administration offers a more patient-friendly dosing option, with the potential to deliver rapid-acting, short-duration relief for anxiety disorders. Drysdale emphasized the significance of intellectual property protection in the biotech sector, noting that Cybin now holds more than 80 granted patents and approximately 220 pending applications. He said this growing portfolio supports the company’s position as a leader in the psychedelic medicine space and helps safeguard its investment in drug development. In addition to the CYB004 program, Cybin is progressing into Phase 3 trials for its lead depression treatment candidate, which has received Breakthrough Therapy Designation from the FDA. The first Phase 3 study is already underway, with a second expected to begin around mid-year. The company is also conducting a separate Phase 2 trial targeting anxiety, with results anticipated in the same timeframe. Drysdale concluded by noting that these milestones mark an important inflection point for the company as it moves closer to bringing new mental health treatments to market. #proactiveinvestors #cybininc #nyseamerican #ctbn #MentalHealth #PsychedelicTherapy #DepressionTreatment #BiotechNews #DougDrysdale #FDAapproval #ClinicalTrials #AnxietyTreatment #ProactiveInvestors